What are the marketing concerns about Vyndamax?
In September 2025 Pfizer was accused of showing a video at a medical meeting describing Vyndamax as the first and only approved treatment — omitting two approved rivals — and a German court ordered it to stop claiming "near-complete stabilisation".
Critics raise concerns about how Vyndamax is described to patients and doctors now that alternatives exist. Patient advocates have objected to language presenting Vyndamax as the "only" once-daily capsule for ATTR-CM, arguing it may lead patients to believe they have fewer options than they do. The same report notes that Pfizer's materials direct patients to Amyloidosis Support Groups, to which Pfizer's historic disclosures show a $50,000 contribution, raising questions about industry funding of advocacy groups. In September 2025 Pfizer was accused of showing a video at a medical meeting describing Vyndamax as the first and only approved treatment, omitting two approved rivals, and that another Pfizer comparison was not based on fair and comparable standards.